Buy Research Chemical Online

AcuraStem Inc., based in Pasadena, CA, is a pioneering biotechnology company focused on developing innovative treatments for neurodegenerative diseases, including sporadic ALS and FTD. Utilizing their proprietary disease-modeling platform, iNeuroRx, AcuraStem emphasizes a patient-based approach that leads to more effective and broadly applicable therapeutic solutions by generating individual patient models that accurately mimic disease processes. With a commitment to advancing drug development, AcuraStem has made significant strides in the field, as demonstrated by recent presentations from their leadership at prominent research summits. Their work aims to address the limitations of traditional animal models, fostering a deeper understanding of the human mechanisms that drive neurodegenerative diseases. Generated from the website

AutoImmune is a biopharmaceutical company engaged in the development of orally administered products that treat autoimmune and other cell-mediated inflammatory diseases. The company s products are based on a common biological mechanism known as oral tolerance, which provides tissue-specific immunosuppression to control disease without toxicity or significant side effects. The company has exclusively licensed certain of its intellectual property rights to BioMS Medical Corporation and Teva Pharmaceutical Industries, which are both engaged in the development and production of treatments for multiple sclerosis. AutoImmune is a publicly traded company. Its shares are listed on the OTC Bulletin Board under the symbol AIMM. AutoImmune is headquartered in Pasadena, Calif.

Lixte Biotechnology Holdings is a publicly traded therapeutic and diagnostics company that focuses on the improvement of treatment options for life-threatening cancers. The company undertakes various biomedical research activities for the development of drugs for cancers. Founded in 2005, Lixte Biotechnology Holdings is engaged in the development of chemotherapy drugs that target molecular abnormalities of cancers in humans. Based on the discovery of biomarkers for brain cancers by collaborators at the National Institutes of Health, the company evaluates drugs for the treatment of cancer in adults and children. It works in partnership with the National Institute of Neurological Disorders and Stroke to study the effectiveness of lead compounds.